ClinicalTrials.Veeva

Menu
C

Clinical Research Institute of Michigan | Chesterfield, MI

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Mirikizumab
Guselkumab
ABX464
GS-1427
MK-7240-001
MK-7240
Rencofilstat
TAK-101
Deudomperidone
Filgotinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 23 total trials

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (E...

Active, not recruiting
Eosinophilic Esophagitis
Procedure: Esophagogastroduodenoscopy
Drug: Placebo oral tablet

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical resp...

Active, not recruiting
Ulcerative Colitis
Drug: Placebo SC
Drug: Mirikizumab SC

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 3
Drug: Placebo
Locations recently updated

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will ha...

Enrolling
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Mirikizumab

The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participant...

Active, not recruiting
Celiac Disease
Drug: TAK-062 Placebo
Dietary Supplement: Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Locations recently updated

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Ustekinumab
Drug: Guselkumab Dose 3
Locations recently updated

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active ulcerative col...

Enrolling
Ulcerative Colitis
Drug: IV Placebo
Drug: SC Placebo

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling
Diabetic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 2

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative col...

Enrolling
Ulcerative Colitis
Drug: Mirikizumab

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinica...

Enrolling
Ulcerative Colitis
Drug: Placebo
Drug: ABX464

The main aim of the study is to assess if TAK-101 can reduce gluten related symptoms and immune activation in adult participants with celiac disease...

Enrolling
Celiac Disease
Dietary Supplement: Gluten
Drug: TAK-101

A randomized, multi-center, double-blind, three arm placebo-controlled study in male and non-pregnant, non-lactating female subjects aged 18 years to...

Enrolling
Ulcerative Proctitis
Combination Product: Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator
Combination Product: Twice daily placebo suppository administered with Sephure applicator

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RVT-3101 in a...

Active, not recruiting
Crohn Disease
Drug: RVT-3101
Locations recently updated

The goal of this study is to learn if GS-1427 is effective and safe in treating participants with moderate to severe ulcerative colitis. The study wi...

Enrolling
Ulcerative Colitis
Drug: Ustekinumab
Drug: Placebo-to-match GS-1427

Trial sponsors

Lilly logo
Janssen (J&J Innovative Medicine) logo
Takeda logo
A
C
C
E
G
Gilead Sciences logo
H

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems